Holen Sie sich die Stockscreener-App
16.23
2.99%
-0.50
Handel nachbörslich:
16.25
0.02
+0.12%
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
(BLCO) Technical Pivots with Risk Controls (BLCO:CA) - Stock Traders Daily
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
Bausch + Lomb abandons glaucoma drops after phase 2 failure - MSN
Bausch + Lomb ditches BL1107 in glaucoma after trial miss - The Pharma Letter
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - Yahoo Finance
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Benzinga
Price to earnings forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - BioSpace
Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates - Yahoo Finance
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform - VisionMonday.com
Bausch + Lomb halts glaucoma eye drop program after trial miss - Investing.com UK
Bausch + Lomb halts glaucoma eye drop program after trial miss By Investing.com - Investing.com South Africa
Bausch + Lomb Ends Glaucoma Eye-Drop Development After Missed Trial Endpoint - Moomoo
Bausch to stop glaucoma eye drop development after trial miss - Reuters
BLCO stock stays supported by diversified eye-health portfolio - ad-hoc-news.de
Bausch + Lomb Corporation - Baystreet.ca
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Bausch + Lomb introduces Orphia, an AI-powered digital health platform - Chain Drug Review
Bausch + Lomb launches AI-powered digital health platform - Investing.com
Bausch + Lomb launches AI-powered digital health platform By Investing.com - Investing.com Canada
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - BioSpace
Bausch + Lomb Corp updates keep long-term strategy in focus - ad-hoc-news.de
Press Release: Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - Moomoo
Bausch + Lomb launches Bi-Blade+ vitrectomy cutter in Europe - Investing.com
(BLCO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Bausch + Lomb Survey Finds That Addressing Dry Eye Symptoms Boosts Confidence, Lowers Anxiety - VisionMonday.com
BLCOBausch + Lomb Corp Volatility & Greeks - Finviz
Bausch + Lomb Corp (BLCO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BLCO News | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Bausch + Lomb survey finds dry eye symptoms linked to emotional health impacts - Optometry Times
BLCO Forecast — Price Target — Prediction for 2027 - TradingView
Bausch + Lomb survey finds dry eye affects emotional health By Investing.com - Investing.com Canada
Dry eye treatment tied to lower anxiety, better confidence in Bausch + Lomb survey - Stock Titan
Bausch + Lomb Corp updates investors on strategic focus, shares trade on NYSE - ad-hoc-news.de
INFUSE silicone hydrogel daily contact lenses from Bausch + Lomb Corp.a moisture-first take on al - ad-hoc-news.de
S2L Forecast — Price Target — Prediction for 2027 - TradingView
Bausch + Lomb Corporation Actuals & Estimates (NYSE:BLCO) - TradingView
Bausch + Lomb Corporation Actuals & Estimates (TSX:BLCO) - TradingView
Bausch + Lomb Tumbles as Technical and Governance Fears Mount - TipRanks
(BLCO) Risk Channels and Responsive Allocation - Stock Traders Daily
INFUSE Multifocal from Bausch + Lomb Corp.daily disposable lens for presbyopia - AD HOC NEWS
Cooper Cos. gains after report activist Jana takes stake - MSN
Bausch + Lomb (BLCO) Consolidates Near Support Following Minimal Daily ChangeFloat Adjusted Cap - dars.gov.et
Bausch + Lomb Corp (BLCO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bausch + Lomb Corp (BLCO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bausch + Lomb Corp (BLCO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bausch + Lomb Corp (BLCO) Institutional Confidence - TradingKey
Bausch + Lomb Corp (BLCO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bausch + Lomb Corp (BLCO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bausch + Lomb Corp (BLCO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bausch + Lomb Corp (BLCO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bausch & Lomb (NYSE: BLCO) executive has 1,008 shares withheld for tax on RSU vesting - Stock Titan
0.71%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):